RxDoctor Payments Data

Rakesh Prasad, MD

Internal Medicine · Oklahoma City, OKNPI 1487639746

Payments from drug & device makers

$7,872in general payments, 2019–2025

Across 430 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$727
  • Boehringer Ingelheim$634
  • AbbVie$489
  • Novo Nordisk$373
  • Lilly USA, LLC$330
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$7,78299%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,872 in reported general payments places this provider in the 90th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$418,791
Medicare patients
689
Services billed
4,913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$110,888
EliquisApixaban99$85,522
JardianceEmpagliflozin30$52,997
FarxigaDapagliflozin Propanediol30$43,374
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$42,399
MounjaroTirzepatide29$40,814
RybelsusSemaglutide14$27,593
JanuviaSitagliptin Phosphate18$22,217
TrulicityDulaglutide11$22,204
Repatha SureclickEvolocumab14$12,047
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$11,581
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$10,870
Breo ElliptaFluticasone/Vilanterol23$9,101
Gabapentin201$3,817
Atorvastatin Calcium312$2,940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$373$138,48195 claims
PfizerEliquis$252$85,52299 claims
Lilly USA, LLCMounjaro, Trulicity$330$63,01840 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,795$54,24441 claims
Boehringer IngelheimJardiance$634$52,99730 claims
GSKTrelegy Ellipta, Breo Ellipta$727$51,50073 claims
MerckJanuvia$54$22,21718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →